Академический Документы
Профессиональный Документы
Культура Документы
Abstract
Four of the water-based dextran-ferrite (DF) magnetic uids (MF) were prepared. Their saturation magnetization
was from 0.9 to 7.5 kA/m; specic power absorption rates were 210 W/g Fe; pH was from 6 to 9 and Zeta-potential (f)
was from +18 to 12 mV. After nine magnetic uid tumor hyperthermia at +441C to +451C, 30 min with waterltered AC magnetic eld (0.88 MHz, 9.3 kA/m, 0.15 kW), while using DF MF (saturation magnetization 7.5 kA/m, pH
6.6, f +15 mV), a complete tumor regression sarcoma MX11 in C57Bl/6j mice was 33%, life span increase achieved was
150%.
r 2002 Elsevier Science B.V. All rights reserved.
Keywords: Sarcoma; Magnetic uid hyperthermia; Dextran-ferrite targetinginhomogeneous permanent magnetic eld (PMF); AC
magnetic eldwater-ltered
1. Introduction
We have developed magnetic dextran-ferrite #363
(DF) nanoparticles for an externally applied AC
magnetic eld hyperthermia [1,2]. DF magnetic uids
(MFs), that had been prepared, were less toxic for
experimental animals [3], so that they may be ideal
magnetic carriers [4]. The particles of DF dissipate
of AC magnetic eld energy through various kinds of
losses and therefore cause hyperthermia in the area of
their connement [1,2, 47]. The survival of MX11 cells
as the function of the exposure time at +441C when
heating DF #363 MFs was achieved by AC magnetic
*Corresponding author.
E-mail addresses: nikitin@magn.ru (L.V. Nikitin), gogosov@imec.msu.ru (T.N. Brusentsova), akuz@sky.chph.ras.ru
(A.A. Kuznetsov), akuz@sky.chph.ras.ru (A.A. Kuznetsov),
akuz@sky.chph.ras.ru (A.A. Kuznetsov), akuz@sky.chph.ras.ru (A.A. Kuznetsov), akuz@sky.chph.ras.ru (A.A. Kuznetsov),
bayburt@mail.ru (F.S. Bayburtskiy).
eld (0.88 MHz, 7.2 kA/m, 0.15 kW) or water bath was
the same [2].
The inevitable technical problem with hyperthermia in
vivo is the difculty of the uniform heating of only the
tumor region until the required temperature without
damaging normal tissue.
The purpose of this work was to evaluate DF #363
MFs for the site-specic AC magnetic eld hyperthermia
of sarcoma MX11 in vivo.
0304-8853/02/$ - see front matter r 2002 Elsevier Science B.V. All rights reserved.
PII: S 0 3 0 4 - 8 8 5 3 ( 0 2 ) 0 0 6 3 4 - 0
N.A. Brusentsov et al. / Journal of Magnetism and Magnetic Materials 252 (2002) 378380
379
treatment
start
45
40
35
30
25
20
15
10
5
0
0
treatment
finish
10 20 30 40 50 60 70 80 90
growth time [days]
group 1,
group 2,
group 3,
group 4
N.A. Brusentsov et al. / Journal of Magnetism and Magnetic Materials 252 (2002) 378380
380
Table 1
Antitumor effect of water-ltered AC magnetic eld treatment on solid MX11 sarcoma tissue that was formed subcutaneously over 36
days after the rst DF #363 MF injection and increase life span (ILS) of female C57Bl/6j mice
Group
Treatment time
(ILS) (%)
1
2
3
4
0
3
3
9
33 4207180
30 0517150
10 242763
9073
1.000
0.899
0.306
0.003
0
0
11
33
0
107
130
150
*Relative tumor volume=(average tumor volume of each group)/(average tumor volume of group 1).
4. Conclusions
Multiple injections of DF MF and PMF DF targeting
in tumor tissues with the following AC magnetic eld
treatment may be necessary in such a case, to achieve
tumor complete regression. The 30% rise of dextranferrite concentration in the tumor tissue, the 33%
complete tumor regression sarcoma MX11 and 150%
increase life span in female C57Bl/6j mice were
shown at the application of the developed DF MF
hyperthermia.
References
[1] N.A. Brusentsov, Mendeleev Chem. J. 35 (1990) 98.
[2] N.A. Brusentsov, V.V. Gogosov, T.N. Brusentsova, et al.,
J. Magn. Magn. Mater. 225 (2001) 113.
[3] O.A. Kuznetsov, N.A. Brusentsov, A.A. Kuznetsov, et al.,
J. Magn. Magn. Mater. 194 (1999) 83.
[4] A. Jordan, P. Wust, R. Scholz, et al., in: Hafeli, et al.
(Eds.), Scientic and Clinical Application of Magnetic
Carriers, Plenum Press, New York, 1997, p. 569.
[5] R. Hergt, W. Andr.a, G.G. dAmbly, et al., IEEE Trans.
Magn. 34 (1998) 3745.
[6] A. Jordan, R. Scholz, P. Wust, et al., J. Magn. Magn.
Mater. 194 (1999) 185.
[7] A. Jordan, R. Scholz, K. Maier-Hauff, et al., J. Magn.
Magn. Mater. 225 (2001) 118.
[8] A.B. Syrkin, S.F. Ushkov, Ju.N. Bulychev, et al., Exp.
Oncol. 12 (1990) 71.
[9] N.A. Brusentsov, V.V. Gogosov, M.V. Lukashevich,
Pharm. Chem. J. 30 (1996) 654.
[10] A.I. Autenshlyus, N.A. Brusentsov, A. Lockshin, J. Magn.
Magn. Mater. 122 (1993) 360.
[11] A.A. Novakova, T.S. Gendler, N.A. Brusentsov, Hyperne Interactions 71 (1992) 1315.
[12] L.F. Larionov, Chemotherapy of Malignant Tumors,
Medical Literature, Moscow, 1962.